Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs.

Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM.

Front Oncol. 2019 Jan 22;9:9. doi: 10.3389/fonc.2019.00009. eCollection 2019.

2.

Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease.

Mukherjee A, Patterson AL, George JW, Carpenter TJ, Madaj ZB, Hostetter G, Risinger JI, Teixeira JM.

Mol Cancer Ther. 2018 Sep;17(9):1995-2003. doi: 10.1158/1535-7163.MCT-17-1255. Epub 2018 Jun 13.

3.

MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT.

Yoo JY, Kang HB, Broaddus RR, Risinger JI, Choi KC, Kim TH.

BMC Cancer. 2018 May 29;18(1):605. doi: 10.1186/s12885-018-4502-7.

4.

Ornithine decarboxylase as a therapeutic target for endometrial cancer.

Kim HI, Schultz CR, Buras AL, Friedman E, Fedorko A, Seamon L, Chandramouli GVR, Maxwell GL, Bachmann AS, Risinger JI.

PLoS One. 2017 Dec 14;12(12):e0189044. doi: 10.1371/journal.pone.0189044. eCollection 2017.

5.

Identification and functional characterization of a novel bipartite nuclear localization sequence in ARID1A.

Bateman NW, Shoji Y, Conrads KA, Stroop KD, Hamilton CA, Darcy KM, Maxwell GL, Risinger JI, Conrads TP.

Biochem Biophys Res Commun. 2016 Jan 1;469(1):114-119. doi: 10.1016/j.bbrc.2015.11.080. Epub 2015 Nov 22.

PMID:
26614907
6.

Proteomics of the human endometrial glandular epithelium and stroma from the proliferative and secretory phases of the menstrual cycle.

Hood BL, Liu B, Alkhas A, Shoji Y, Challa R, Wang G, Ferguson S, Oliver J, Mitchell D, Bateman NW, Zahn CM, Hamilton CA, Payson M, Lessey B, Fazleabas AT, Maxwell GL, Conrads TP, Risinger JI.

Biol Reprod. 2015 Apr;92(4):106. doi: 10.1095/biolreprod.114.127217. Epub 2015 Feb 18.

PMID:
25695723
7.

MicroRNAs in endometrial cancers from black and white patients.

Maxwell GL, Shoji Y, Darcy K, Litzi T, Berchuck A, Hamilton CA, Conrads TP, Risinger JI.

Am J Obstet Gynecol. 2015 Feb;212(2):191.e1-10. doi: 10.1016/j.ajog.2014.08.028. Epub 2014 Aug 28.

PMID:
25174797
8.

Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.

Peng M, Zhang H, Jaafar L, Risinger JI, Huang S, Mivechi NF, Ko L.

J Biol Chem. 2013 Nov 15;288(46):33387-97. doi: 10.1074/jbc.M113.485581. Epub 2013 Oct 4.

9.

Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion.

Risinger JI, Allard J, Chandran U, Day R, Chandramouli GV, Miller C, Zahn C, Oliver J, Litzi T, Marcus C, Dubil E, Byrd K, Cassablanca Y, Becich M, Berchuck A, Darcy KM, Hamilton CA, Conrads TP, Maxwell GL.

Front Oncol. 2013 Jun 17;3:139. doi: 10.3389/fonc.2013.00139. eCollection 2013.

10.

Gene expression in uterine leiomyoma from tumors likely to be growing (from black women over 35) and tumors likely to be non-growing (from white women over 35).

Davis BJ, Risinger JI, Chandramouli GV, Bushel PR, Baird DD, Peddada SD.

PLoS One. 2013 Jun 13;8(6):e63909. doi: 10.1371/journal.pone.0063909. Print 2013.

11.

Transcript expression in endometrial cancers from Black and White patients.

Maxwell GL, Allard J, Gadisetti CV, Litzi T, Casablanca Y, Chandran U, Darcy KM, Levine DA, Berchuck A, Hamilton CA, Conrads TP, Risinger JI.

Gynecol Oncol. 2013 Jul;130(1):169-73. doi: 10.1016/j.ygyno.2013.04.017. Epub 2013 Apr 17.

PMID:
23603370
12.

Normal viability of Kai1/Cd82 deficient mice.

Risinger JI, Custer M, Feigenbaum L, Simpson RM, Hoover SB, Webster JD, Chandramouli GV, Tessarollo L, Barrett JC.

Mol Carcinog. 2014 Aug;53(8):610-24. doi: 10.1002/mc.22009. Epub 2013 Feb 8.

PMID:
23401136
13.

Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility.

Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, Rubin JS, Niederhuber J.

Oncogene. 2013 Jul 4;32(27):3246-53. doi: 10.1038/onc.2012.351. Epub 2012 Aug 13.

14.

Analysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer.

Allard JE, Chandramouli GV, Stagliano K, Hood BL, Litzi T, Shoji Y, Boyd J, Berchuck A, Conrads TP, Maxwell GL, Risinger JI.

Front Oncol. 2012 Jul 4;2:65. doi: 10.3389/fonc.2012.00065. eCollection 2012.

15.

PPP2R1A mutations are common in the serous type of endometrial cancer.

Nagendra DC, Burke J 3rd, Maxwell GL, Risinger JI.

Mol Carcinog. 2012 Oct;51(10):826-31. doi: 10.1002/mc.20850. Epub 2011 Aug 31.

PMID:
21882256
16.

Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation.

Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, Bateman NW, Allard J, Miller C, Sun M, Flint MS, Zahn C, Oliver J, Banerjee S, Litzi T, Parwani A, Sandburg G, Rose S, Becich MJ, Berchuck A, Kohn E, Risinger JI, Conrads TP.

Gynecol Oncol. 2011 Jun 1;121(3):586-94. doi: 10.1016/j.ygyno.2011.02.031. Epub 2011 Apr 1.

PMID:
21458040
17.

The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts.

Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J.

Cell Cycle. 2010 Nov 1;9(21):4387-98. Epub 2010 Nov 17.

18.

Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.

Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Risinger JI, Thigpen JT, Fleming GF, Gallion HH, Maxwell GL.

Cancer. 2010 Jan 15;116(2):355-61. doi: 10.1002/cncr.24769.

19.

Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.

Wei BR, Hoover SB, Ross MM, Zhou W, Meani F, Edwards JB, Spehalski EI, Risinger JI, Alvord WG, QuiƱones OA, Belluco C, Martella L, Campagnutta E, Ravaggi A, Dai RM, Goldsmith PK, Woolard KD, Pecorelli S, Liotta LA, Petricoin EF, Simpson RM.

PLoS One. 2009 Oct 30;4(10):e7670. doi: 10.1371/journal.pone.0007670.

20.

Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, Risinger JI, Barrett JC, Niederhuber J.

Cancer Res. 2009 Jan 15;69(2):616-24. doi: 10.1158/0008-5472.CAN-08-0811.

21.

Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy?

Maxwell GL, Tian C, Risinger JI, Hamilton CA, Barakat RR; Gynecologic Oncology Group Study.

Cancer. 2008 Sep 15;113(6):1431-7. doi: 10.1002/cncr.23717.

22.

Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.

Allard JE, Risinger JI, Morrison C, Young G, Rose GS, Fowler J, Berchuck A, Maxwell GL.

Gynecol Oncol. 2007 Oct;107(1):52-7. Epub 2007 Jun 20.

PMID:
17582475
23.

Racial disparities in blacks with gynecologic cancers.

Farley J, Risinger JI, Rose GS, Maxwell GL.

Cancer. 2007 Jul 15;110(2):234-43.

24.

Evolutionary diversification of SPANX-N sperm protein gene structure and expression.

Kouprina N, Noskov VN, Pavlicek A, Collins NK, Schoppee Bortz PD, Ottolenghi C, Loukinov D, Goldsmith P, Risinger JI, Kim JH, Westbrook VA, Solomon G, Sounders H, Herr JC, Jurka J, Lobanenkov V, Schlessinger D, Larionov V.

PLoS One. 2007 Apr 4;2(4):e359.

25.

Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.

Dainty LA, Risinger JI, Morrison C, Chandramouli GV, Bidus MA, Zahn C, Rose GS, Fowler J, Berchuck A, Maxwell GL.

Gynecol Oncol. 2007 Jun;105(3):563-70. Epub 2007 Apr 2.

PMID:
17400285
26.

Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.

Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC.

Clin Cancer Res. 2007 Mar 15;13(6):1713-9.

27.
28.

Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.

Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC.

Gynecol Oncol. 2006 Nov;103(2):535-40. Epub 2006 Jun 5.

PMID:
16740300
29.

Racial disparities research: it's not just black and white.

Maxwell GL, Risinger JI.

Gynecol Oncol. 2006 May;101(2):194-7. No abstract available.

PMID:
16701108
30.

Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray.

Bidus MA, Risinger JI, Chandramouli GV, Dainty LA, Litzi TJ, Berchuck A, Barrett JC, Maxwell GL.

Clin Cancer Res. 2006 Jan 1;12(1):83-8.

31.

Characterization of an antibody that can detect the Kai1/CD82 murine metastasis suppressor.

Custer MC, Risinger JI, Hoover S, Simpson RM, Patterson T, Barrett JC.

Prostate. 2006 May 1;66(6):567-77.

PMID:
16372335
32.

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.

Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.

Cancer Res. 2005 Sep 1;65(17):7763-74.

33.

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.

Cancer Res. 2005 Sep 1;65(17):7751-62.

34.

The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein.

Kouprina N, Pavlicek A, Collins NK, Nakano M, Noskov VN, Ohzeki J, Mochida GH, Risinger JI, Goldsmith P, Gunsior M, Solomon G, Gersch W, Kim JH, Barrett JC, Walsh CA, Jurka J, Masumoto H, Larionov V.

Hum Mol Genet. 2005 Aug 1;14(15):2155-65. Epub 2005 Jun 22.

PMID:
15972725
35.

Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.

Risinger JI, Maxwell GL, Chandramouli GV, Aprelikova O, Litzi T, Umar A, Berchuck A, Barrett JC.

Cancer Res. 2005 Jun 15;65(12):5031-7.

36.

Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.

Maxwell GL, Chandramouli GV, Dainty L, Litzi TJ, Berchuck A, Barrett JC, Risinger JI.

Clin Cancer Res. 2005 Jun 1;11(11):4056-66.

37.

The SPANX gene family of cancer/testis-specific antigens: rapid evolution and amplification in African great apes and hominids.

Kouprina N, Mullokandov M, Rogozin IB, Collins NK, Solomon G, Otstot J, Risinger JI, Koonin EV, Barrett JC, Larionov V.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3077-82. Epub 2004 Feb 18.

38.

Testing guidelines for hereditary non-polyposis colorectal cancer.

Umar A, Risinger JI, Hawk ET, Barrett JC.

Nat Rev Cancer. 2004 Feb;4(2):153-8. doi: 10.1038/nrc1278. Review. No abstract available.

PMID:
14964310
39.

Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.

Risinger JI, Maxwell GL, Berchuck A, Barrett JC.

Ann N Y Acad Sci. 2003 Mar;983:208-12. Review.

PMID:
12724225
40.

Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.

Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC.

Cancer Res. 2003 Jan 1;63(1):6-11.

41.

Cell proliferation and apoptosis in human uterine leiomyomas and myometria.

Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC, Robboy SJ.

Virchows Arch. 2002 Jul;441(1):53-62. Epub 2002 Mar 23.

PMID:
12111201
42.

Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics.

Carney SA, Tahara H, Swartz CD, Risinger JI, He H, Moore AB, Haseman JK, Barrett JC, Dixon D.

Lab Invest. 2002 Jun;82(6):719-28.

43.

Splice variants but not mutations of DNA polymerase beta are common in bladder cancer.

Thompson TE, Rogan PK, Risinger JI, Taylor JA.

Cancer Res. 2002 Jun 1;62(11):3251-6.

44.

Expression of Gab1 lacking the pleckstrin homology domain is associated with neoplastic progression.

Kameda H, Risinger JI, Han BB, Baek SJ, Barrett JC, Abe T, Takeuchi T, Glasgow WC, Eling TE.

Mol Cell Biol. 2001 Oct;21(20):6895-905.

45.

Identification of epidermal growth factor receptor- Grb2-associated binder-1-SHP-2 complex formation and its functional loss during neoplastic cell progression.

Kameda H, Risinger JI, Han BB, Baek SJ, Barrett JC, Glasgow WC, Eling TE.

Cell Growth Differ. 2001 Jun;12(6):307-18.

46.

Mutational analysis of the PTEN gene in human uterine sarcomas.

Lancaster JM, Risinger JI, Carney ME, Barrett JC, Berchuck A.

Am J Obstet Gynecol. 2001 May;184(6):1051-3.

PMID:
11349153
47.

Favorable survival associated with microsatellite instability in endometrioid endometrial cancers.

Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A.

Obstet Gynecol. 2001 Mar;97(3):417-22.

PMID:
11239648
48.

Advances in uterine leiomyoma research: conference overview, summary, and future research recommendations.

Newbold RR, DiAugustine RP, Risinger JI, Everitt JI, Walmer DK, Parrott EC, Dixon D.

Environ Health Perspect. 2000 Oct;108 Suppl 5:769-73. Review.

49.

Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.

Maxwell GL, Risinger JI, Hayes KA, Alvarez AA, Dodge RK, Barrett JC, Berchuck A.

Clin Cancer Res. 2000 Aug;6(8):2999-3005.

50.

The linoleic acid metabolite, 13-HpODE augments the phosphorylation of EGF receptor and SHP-2 leading to their increased association.

Hui R, Kameda H, Risinger JI, Angerman-Stewart J, Han B, Barrett JC, Eling TE, Glasgow WC.

Prostaglandins Leukot Essent Fatty Acids. 1999 Aug;61(2):137-43.

PMID:
10509870

Supplemental Content

Loading ...
Support Center